open access

Vol 1, No 1 (2005)
Review paper
Published online: 2005-05-17
Get Citation

Progress in therapy of chronic myeloid leukemia

Ilona Seferyńska, Krzysztof Warzocha
Onkol. Prak. Klin 2005;1(1):40-48.

open access

Vol 1, No 1 (2005)
REVIEW ARTICLES
Published online: 2005-05-17

Abstract

Allogeneic hematopoietic stem cell transplantation from related or unrelated donors remains the only potentially curative treatment option in chronic myeloid leukemia (CML). This procedure is limited by the availability of the donor and toxicity, especially in older patients. Introduction of signal transduction inhibitor — imatinib in the management of CML has revised the choice of therapy for newly diagnosed patients. Results of the Phase III study showed 96% complete hematologic and 76.2% complete cytogenetic responses. However, only a minority of imatinib-treated patients achieved molecular remission and definite conclusions cannot be made at this time. Treatment with alpha-interferon (IFN-α) prolongs survival by approximately 2 years as compared with conventional chemotherapy. The response rate is better if the treatment with IFN-α is combined with low dose of cytarabine. Conventional chemotherapy with hydroxyurea or busulfan is a cytoreductive therapy, which does not significantly modify the natural course of the disease.

Abstract

Allogeneic hematopoietic stem cell transplantation from related or unrelated donors remains the only potentially curative treatment option in chronic myeloid leukemia (CML). This procedure is limited by the availability of the donor and toxicity, especially in older patients. Introduction of signal transduction inhibitor — imatinib in the management of CML has revised the choice of therapy for newly diagnosed patients. Results of the Phase III study showed 96% complete hematologic and 76.2% complete cytogenetic responses. However, only a minority of imatinib-treated patients achieved molecular remission and definite conclusions cannot be made at this time. Treatment with alpha-interferon (IFN-α) prolongs survival by approximately 2 years as compared with conventional chemotherapy. The response rate is better if the treatment with IFN-α is combined with low dose of cytarabine. Conventional chemotherapy with hydroxyurea or busulfan is a cytoreductive therapy, which does not significantly modify the natural course of the disease.
Get Citation

Keywords

chronic myelogenous leukemia; hematopoietic stem cell transplantation; imatinib; interferon; hydroxyurea; busulfan

About this article
Title

Progress in therapy of chronic myeloid leukemia

Journal

Oncology in Clinical Practice

Issue

Vol 1, No 1 (2005)

Article type

Review paper

Pages

40-48

Published online

2005-05-17

Bibliographic record

Onkol. Prak. Klin 2005;1(1):40-48.

Keywords

chronic myelogenous leukemia
hematopoietic stem cell transplantation
imatinib
interferon
hydroxyurea
busulfan

Authors

Ilona Seferyńska
Krzysztof Warzocha

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl